Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06240754 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Enasidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH2A Decentralized Trial

Name: Enasidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH2A Decentralized Trial — clinical trial record (NCT06240754)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 2

SponsorWashington University School of Medicine

Started2024-10-10

View on ClinicalTrials.gov ↗

Study researchers think that a drug called enasidenib may help people with clonal cytopenia of undetermined significance (CCUS) because the drug blocks the mutated IDH2 protein, which may improve blood cell counts. The purpose of this study is to find out whether enasidenib is a safe and effective treatment for CCUS.

Amendment history 2 changes detected by DataLookout

2026-08-11

Primary completion pushed: 2028-01-31 → 2028-05-31

2026-08-11

Completion pushed: 2029-02-28 → 2029-06-30

Trial Details

NCT Number	NCT06240754
Lead Sponsor	Washington University School of Medicine Collaborators: Bristol-Myers Squibb, Damon Runyon Cancer Research Foundation
Conditions	Clonal Cytopenia of Undetermined Significance, CCUS Clonal Cytopenia of Undetermined Significance
Enrollment	15 participants
Start Date	2024-10-10
Primary Completion	2028-05-31 (estimated)
Study Completion	2029-06-30 (estimated)
Updated on ClinicalTrials.gov	2026-08-10